Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 6 studies | 23% ± 7% | |
glutamatergic neuron | 6 studies | 32% ± 19% | |
hematopoietic precursor cell | 5 studies | 23% ± 7% | |
epithelial cell | 5 studies | 36% ± 16% | |
plasmacytoid dendritic cell | 5 studies | 20% ± 4% | |
erythroblast | 4 studies | 32% ± 10% | |
natural killer cell | 4 studies | 21% ± 4% | |
retina horizontal cell | 4 studies | 23% ± 9% | |
dendritic cell | 4 studies | 33% ± 10% | |
CD4-positive, alpha-beta T cell | 4 studies | 23% ± 8% | |
CD8-positive, alpha-beta T cell | 4 studies | 21% ± 5% | |
conventional dendritic cell | 3 studies | 34% ± 11% | |
precursor B cell | 3 studies | 19% ± 2% | |
pro-B cell | 3 studies | 20% ± 2% | |
fibroblast | 3 studies | 22% ± 4% | |
GABAergic neuron | 3 studies | 38% ± 11% | |
intestinal crypt stem cell | 3 studies | 19% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 6001.84 | 180 / 180 | 100% | 129.57 | 430 / 430 |
prostate | 100% | 6259.26 | 245 / 245 | 100% | 259.52 | 502 / 502 |
skin | 100% | 7800.62 | 1809 / 1809 | 100% | 193.21 | 472 / 472 |
esophagus | 100% | 5376.26 | 1444 / 1445 | 100% | 131.99 | 183 / 183 |
thymus | 100% | 4514.52 | 652 / 653 | 100% | 167.06 | 605 / 605 |
uterus | 100% | 5449.50 | 170 / 170 | 100% | 202.79 | 458 / 459 |
stomach | 100% | 4072.63 | 359 / 359 | 100% | 172.98 | 285 / 286 |
breast | 100% | 5213.31 | 459 / 459 | 100% | 230.99 | 1114 / 1118 |
intestine | 100% | 4792.37 | 966 / 966 | 100% | 199.62 | 525 / 527 |
liver | 100% | 3425.19 | 225 / 226 | 100% | 109.16 | 406 / 406 |
brain | 100% | 6738.75 | 2630 / 2642 | 100% | 185.23 | 705 / 705 |
pancreas | 100% | 3537.91 | 327 / 328 | 99% | 133.95 | 177 / 178 |
adrenal gland | 100% | 6350.78 | 258 / 258 | 99% | 152.69 | 228 / 230 |
kidney | 100% | 3364.09 | 89 / 89 | 99% | 99.08 | 893 / 901 |
bladder | 100% | 5764.76 | 21 / 21 | 99% | 194.16 | 498 / 504 |
lung | 99% | 3691.55 | 574 / 578 | 99% | 164.97 | 1147 / 1155 |
adipose | 100% | 4466.02 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 174.99 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 268.25 | 29 / 29 |
spleen | 100% | 5339.09 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 199.55 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 111.40 | 1 / 1 |
muscle | 100% | 4339.28 | 802 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4057.57 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 96% | 2544.73 | 827 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 87% | 3852.13 | 812 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006303 | Biological process | double-strand break repair via nonhomologous end joining |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0000244 | Biological process | spliceosomal tri-snRNP complex assembly |
GO_0010498 | Biological process | proteasomal protein catabolic process |
GO_0008610 | Biological process | lipid biosynthetic process |
GO_0048026 | Biological process | positive regulation of mRNA splicing, via spliceosome |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_0008104 | Biological process | protein localization |
GO_0000245 | Biological process | spliceosomal complex assembly |
GO_0000077 | Biological process | DNA damage checkpoint signaling |
GO_0005811 | Cellular component | lipid droplet |
GO_0005681 | Cellular component | spliceosomal complex |
GO_0016020 | Cellular component | membrane |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0071007 | Cellular component | U2-type catalytic step 2 spliceosome |
GO_0000974 | Cellular component | Prp19 complex |
GO_0071006 | Cellular component | U2-type catalytic step 1 spliceosome |
GO_0005737 | Cellular component | cytoplasm |
GO_0071013 | Cellular component | catalytic step 2 spliceosome |
GO_0005662 | Cellular component | DNA replication factor A complex |
GO_0035861 | Cellular component | site of double-strand break |
GO_0005819 | Cellular component | spindle |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0034450 | Molecular function | ubiquitin-ubiquitin ligase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PRPF19 |
Protein name | Pre-mRNA-processing factor 19 (EC 2.3.2.27) Pre-mRNA-processing factor 19 (EC 2.3.2.27) (Nuclear matrix protein 200) (PRP19/PSO4 homolog) (hPso4) (RING-type E3 ubiquitin transferase PRP19) (Senescence evasion factor) |
Synonyms | SNEV PRP19 NMP200 |
Description | FUNCTION: Ubiquitin-protein ligase which is a core component of several complexes mainly involved pre-mRNA splicing and DNA repair. Required for pre-mRNA splicing as component of the spliceosome . Core component of the PRP19C/Prp19 complex/NTC/Nineteen complex which is part of the spliceosome and participates in its assembly, its remodeling and is required for its activity. During assembly of the spliceosome, mediates 'Lys-63'-linked polyubiquitination of the U4 spliceosomal protein PRPF3. Ubiquitination of PRPF3 allows its recognition by the U5 component PRPF8 and stabilizes the U4/U5/U6 tri-snRNP spliceosomal complex . Recruited to RNA polymerase II C-terminal domain (CTD) and the pre-mRNA, it may also couple the transcriptional and spliceosomal machineries . The XAB2 complex, which contains PRPF19, is also involved in pre-mRNA splicing, transcription and transcription-coupled repair . Beside its role in pre-mRNA splicing PRPF19, as part of the PRP19-CDC5L complex, plays a role in the DNA damage response/DDR. It is recruited to the sites of DNA damage by the RPA complex where PRPF19 directly ubiquitinates RPA1 and RPA2. 'Lys-63'-linked polyubiquitination of the RPA complex allows the recruitment of the ATR-ATRIP complex and the activation of ATR, a master regulator of the DNA damage response . May also play a role in DNA double-strand break (DSB) repair by recruiting the repair factor SETMAR to altered DNA . As part of the PSO4 complex may also be involved in the DNA interstrand cross-links/ICLs repair process . In addition, may also mediate 'Lys-48'-linked polyubiquitination of substrates and play a role in proteasomal degradation . May play a role in the biogenesis of lipid droplets (By similarity). May play a role in neural differentiation possibly through its function as part of the spliceosome (By similarity). . FUNCTION: Ubiquitin-protein ligase which is mainly involved pre-mRNA splicing and DNA repair. Required for pre-mRNA splicing as component of the spliceosome. . FUNCTION: Ubiquitin-protein ligase which is mainly involved pre-mRNA splicing and DNA repair. Required for pre-mRNA splicing as component of the spliceosome. . FUNCTION: Ubiquitin-protein ligase which is mainly involved pre-mRNA splicing and DNA repair. Required for pre-mRNA splicing as component of the spliceosome. . FUNCTION: Ubiquitin-protein ligase which is mainly involved pre-mRNA splicing and DNA repair. Required for pre-mRNA splicing as component of the spliceosome. . |
Accessions | ENST00000227524.9 F5GY56 ENST00000535326.1 H0YGF3 ENST00000546152.1 Q9UMS4 F5H2I0 H0YGZ5 ENST00000541371.5 ENST00000540473.5 |